SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.

Citation data:

Journal of hematology & oncology, ISSN: 1756-8722, Vol: 2, Issue: 1, Page: 8

Publication Year:
2009
Usage 149
Downloads 126
Abstract Views 23
Captures 9
Readers 9
Citations 20
Citation Indexes 20
Repository URL:
https://works.bepress.com/anton_scott_goustin/1; https://digitalcommons.wayne.edu/biomedcentral/132
PMID:
19220884
DOI:
10.1186/1756-8722-2-8
PMCID:
PMC2651908
Author(s):
Al-Katib, Ayad M; Sun, Yuan; Goustin, Anton Scott; Azmi, Asfar Sohail; Chen, Ben; Aboukameel, Amro; Mohammad, Ramzi M
Publisher(s):
Springer Nature
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology; Oncology
article description
The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-2 against a range spectrum of human B-cell lines, fresh patient samples and animal xenograft models. Multiple cytochemical and molecular approaches such as acridine orange/ethidium bromide assay for apoptosis, co-immunoprecipitation of complexes and western blot analysis, caspase luminescent activity assay and apoptotic DNA fragmentation assay were used to demonstrate the effect of TW-37 on different B-cell lines, patient derived samples, as well as in animal xenograft models. Nanomolar concentrations of TW-37 were able to induce apoptosis in both fresh samples and established cell lines with IC50 in most cases of 165-320 nM. Apoptosis was independent of proliferative status or pathological classification of B-cell tumor. TW-37 was able to block Bim-Bcl-XL and Bim-Mcl-1 heterodimerization and induced apoptosis via activation of caspases -9, -3, PARP and DNA fragmentation. TW-37 administered to tumor-bearing SCID mice led to significant tumor growth inhibition (T/C), tumor growth delay (T-C) and Log10kill, when used at its maximum tolerated dose (40 mg/kg x 3 days) via tail vein. TW-37 failed to induce changes in the Bcl-2 proteins levels suggesting that assessment of baseline Bcl-2 family proteins can be used to predict response to the drug. These findings indicate activity of TW-37 across the spectrum of human B-cell tumors and support the concept of targeting the Bcl-2 system as a therapeutic strategy regardless of the stage of B-cell differentiation.